Benralizumab Exacerbation Study

  • Research type

    Research Study

  • Full title

    Asthma Exacerbation Profile in patients on open label treatment with Benralizumab for severe eosinophilic asthma - an exploratory cohort study



  • Contact name

    Rekha Chaudhuri

  • Contact email

  • Sponsor organisation

    NHS Greater Glasgow and Clyde

  • Eudract number


  • Duration of Study in the UK

    2 years, 10 months, 2 days

  • Research summary

    Asthma, a common inflammatory condition, is usually well managed with inhaled corticosteroids that target eosinophilic inflammation. In severe asthma cases the management and prevention of exacerbations still presents a problem. This study aims to understand the nature of asthma exacerbations that occur despite benralizumab therapy to help improve severe asthma management.

    The study will involve 150 patients recruited from severe asthma clinics in NHS hospitals UK wide. Participants will receive benralizumab treatment for either 56 or 80 weeks.

  • REC name

    London - Harrow Research Ethics Committee

  • REC reference


  • Date of REC Opinion

    13 Jun 2019

  • REC opinion

    Further Information Favourable Opinion

Shape the future of the HRA website.